AstraZeneca and Sanofi Ask 340B ADR Panel to Dismiss Health Centers’ Overcharging Claims

AstraZeneca and Sanofi asked a 340B administrative dispute resolution panel to dismiss NACHC’s claims its members are being overcharged due to the companies’ 340B contract pharmacies policies.

Drug manufacturers AstraZeneca and Sanofi have asked a 340B administrative dispute resolution panel to dismiss the National Association of Community Health Centers’ claims that its members are being overcharged due to the companies’ denied or restricted 340B sales

Read More »

GlaxoSmithKline Ending Voluntary 340B Pricing on Two Orphan Drugs

GlaxoSmithKline is ending voluntary 340B pricing for rural and cancer hospitals on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

In a blow to rural and cancer hospitals, U.K. drug manufacturer GlaxoSmithKline (GSK) is ending voluntary 340B pricing for them on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

Read More »

Generic-drug Maker e5 Pharma Offering Refunds for 340B Overcharges

e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021.

Generic drug maker e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.

Read More »

Judge’s 340B Statutory Interpretation Was “Exactly Backward,” Lilly Tells Appeals Court

Lilly told a federal appeals court its decision in the drug company's 340B contract pharmacy lawsuit "will have profound consequences for the integrity of the national healthcare system."

A federal district court’s ruling last October that federal law requires drug manufacturers to deliver 340B purchased drugs to contract pharmacies conflicts with two other courts’ conclusions, “upsets the delicate statutory balance Congress struck, and raises serious constitutional

Read More »

Groups Blast PBMs’ Discrimination Against 340B Hospitals in Letters to FTC

Groups that represent or work with 340B hospitals urged the FTC to take a closer look at PBMs' alleged discriminatory business practices.

Pharmacy benefit managers’ discriminatory business practices against 340B hospitals boost PBMs’ financial bottom lines while hurting the hospitals’ mission to serve vulnerable patients, groups that represent or work with 340B hospitals and their pharmacists recently told the Federal

Read More »

340B Report Publisher and CEO: Momentum for 340B Protections Is Growing

340B healthcare providers have turned to the states to address challenges to the drug discount program, 340B Report Publisher and CEO Ted Slafsky says.

Safety net healthcare providers increasingly have turned to the states to address challenges to the 340B program, 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.

Read More »

NEJM Article Says HIV Prevention Should Rely Less on 340B Revenue

An opinion article in the New England Journal of Medicine says overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options. Some HIV/AIDS care providers say high drug prices are the problem, not 340B.

Overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options, “with dire consequences for [preexposure prophylaxis] PrEP access, impact, and equity,” says an opinion article published last

Read More »

BMS and Merck Announce Refunds for 340B Overcharges

BMS and Merck—both for the second time this year—are giving 340B covered entities refunds for overcharges on select products.

Drug manufacturers Bristol Myers Squibb (BMS) and Merck are giving 340B covered entities refunds for overcharges on select products, according to public notices by the companies posted on the U.S. Health Resources and Services Administration (HRSA) website.

Read More »

With Talk of Legislation Heating Up, PhRMA Seeks a New 340B Policy Director

PhRMA is seeking a new director for its policy and research team to help develop and lead implementation of work on 340B.

Pharmaceutical Research and Manufacturers of America (PhRMA) is seeking a new director for its policy and research team to help develop and lead implementation of work on 340B and related hospital cost and affordability issues, according to an

Read More »

340B ADR Proposed Rule Remains at White House 5 Months Past Expected Publication Date

A proposed replacement for the 340B administrative dispute resolution process has been under White House review for more than six months.

A proposed replacement for the 340B administrative dispute resolution (ADR) process has been under White House review for more than half a year. It seems to be no closer to publication for notice and comment than it was

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report